Article Text
Abstract
Rationale Placebo responses are complex psychobiological phenomena and often involve patient expectation of benefit. With continuous positive airway pressure (CPAP) treatment of obstructive sleep apnoea, greater hours of CPAP use are associated with reduced sleepiness. However, these open-label studies have not controlled for patient expectation of benefit derived from their knowledge of hours of device use.
Objectives To investigate the relative effectiveness of the use of real or placebo CPAP on daytime sleepiness.
Methods Patient-level meta-analysis combining data on sleepiness measured by the Epworth Sleepiness Scale from three randomised placebo-controlled crossover trials. Mixed model analysis of variance was used to quantify the effects of real versus placebo device treatment, usage, their interaction and regression to the mean.
Measurements and main results Duration of real and placebo CPAP use was correlated within patients (r=0.53, p<0.001). High use of real CPAP reduced sleepiness more than high use of placebo (difference 3.0 points; 95% CI 1.7 to 4.3, p<0.001) and more than low use of real CPAP (difference 3.3; 95% CI 1.9 to 4.7, p<0.0001). High use of placebo was superior to low use of placebo (difference 1.5; 95% CI 0.1 to 2.8, p=0.03). Twenty-nine per cent of the effect of high usage of CPAP (4.2 points; 95% CI 3.3 to 5.1) was explained by the expectation of benefit effect associated with high use of placebo (1.2 points ; 95% CI 0.2 to 2.3).
Conclusions A clinically significant proportion of the effectiveness of high CPAP use in reducing sleepiness is probably caused by patient expectation of benefit.
- Adherence
- compliance
- placebo effects
- dose–response
- psychology
- respiratory measurement
- sleep apnoea
- clinical epidemiology
- oxidative stress
- assisted ventilation
- pneumonia
- rare lung diseases
- non-invasive ventilation
- COPD exacerbations
- emphysema
- asthma
- ambulatory oxygen therapy
- COPD pharmacology
- long term oxygen therapy
- lung physiology
- respiratory muscles
- short burst oxygen therapy
Statistics from Altmetric.com
- Adherence
- compliance
- placebo effects
- dose–response
- psychology
- respiratory measurement
- sleep apnoea
- clinical epidemiology
- oxidative stress
- assisted ventilation
- pneumonia
- rare lung diseases
- non-invasive ventilation
- COPD exacerbations
- emphysema
- asthma
- ambulatory oxygen therapy
- COPD pharmacology
- long term oxygen therapy
- lung physiology
- respiratory muscles
- short burst oxygen therapy
Footnotes
A version of this study has been presented in poster format at the 20th Congress of the European Sleep Research Society, Lisbon, Portugal, September 2010, at the Australasian Sleep Association meeting in Christchurch, New Zealand, October 2010 and at the World Sleep Federation meeting in Kyoto, Japan, October 2011.
Funding The Health Research Council of New Zealand (grant 00/285); The National Health and Medical Research Council of Australia (grants 202916; 301936; 457355; 571179; 571421 and 512498); British Heart Foundation (grant 2001).
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.